SillaJen's December IPO: Valuation, Growth Expectation and IPO Timing
SillaJen Biotherapeutics (established in 2006) is indeed a rare breed in Korean pharmaceutical world. It is not a generic drug maker. It is not a...
3.6k Views
What the IPOs Completed in Korea Stock Exchange in 1H 2016 Reveal....
If you want to outperform the market, perhaps you should take a look at the IPO market in Korea. In the midst of difficult global IPO markets, the...
404 Views
Study Highlights Hurdles to U.S. Uptake of Inflectra
A new study (abstract attached) presented at the European Union League Against Rheumatism (EULAR) Conference highlights one of the main hurdles to...
246 Views
Korea Stock Market Monthly Recap #2 - (May 2016)
Our portfolio of top picks were up on average 9.5% in May versus KOSPI which was down 0.5% in the same period. Our top picks in the Korean...
273 Views
Why Be Optimistic if the Payers Are Cautious?
Recent comments from one of the largest health insurers in the U.S. reinforce our view that management's expectations for Remsima (U.S. name...
270 Views